Financial

News

Shares in GSK fell on a decline in vaccine sales in Q3, although demand for other drugs was strong with signs that its revamp is starting to deliver.

News

Novartis's third-quarter results included a $1.9bn impairment relating to its $12bn takeover of Avidity, though CEO insists it remains a good deal.

News

Roche's Q3 pharma sales rose a healthy 7%, although the first signs of weakness for blockbuster product Xolair are a warning of tougher times ahead.

News

Eli Lilly has posted another record quarter of revenue growth, up 48% to $23bn, with Mounjaro and Zepbound now making up two-thirds of the total.

News

Novo Nordisk's better-than-expected second-quarter revenues can't outweigh worries about oral Wegovy growth and another CagriSema disappointment.

News

Pfizer's second-quarter results update is headlined by news of an additional $2.5 billion in cost-cutting initiatives.